Base de dados : MEDLINE
Pesquisa : D27.505.954.427.637 [Categoria DeCS]
Referências encontradas : 4249 [refinar]
Mostrando: 1 .. 10   no formato [Detalhado]

página 1 de 425 ir para página                         

  1 / 4249 MEDLINE  
              next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28452903
[Au] Autor:Maschio M; Dinapoli L; Zarabla A; Maialetti A; Giannarelli D; Fabi A; Vidiri A; Cantelmi T
[Ad] Endereço:*Center for Tumor-Related Epilepsy, UOSD Neurology, †Biostatistic Unit, Departments of ‡Oncology, §Radiology, and ∥Service of Psychiatry, Regina Elena National Cancer Institute, Rome, Italy.
[Ti] Título:Zonisamide in Brain Tumor-Related Epilepsy: An Observational Pilot Study.
[So] Source:Clin Neuropharmacol;40(3):113-119, 2017 May/Jun.
[Is] ISSN:1537-162X
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:OBJECTIVES: Epilepsy heavily affects the quality of life (QoL) of patients with brain tumor because in addition to taking treatments for the oncological illness, patients are required to live with the long-term taking of antiepileptic drugs (AEDs). The AEDs' adverse effects are common in these patients and can negatively influence their perceptions of their QoL.We conducted an observational pilot study in patients with brain tumor-related epilepsy to verify efficacy, tolerability, and impact on QoL and global neurocognitive performances of zonisamide (ZNS) in add-on. MATERIALS AND METHODS: We recruited 13 patients (5 females, 8 males; mean age, 49.6 years) presenting uncontrolled seizures. At first visit and at final follow-up at 6 months, patients underwent neurological examination, evaluation of adverse events, and cognitive and QoL tests. A seizure diary was given. RESULTS: Eight patients underwent chemotherapy, 3 underwent radiotherapy, and 5 had disease progression. Mean dosage of ZNS at final follow-up was 300 mg/d.Of 9 patients who reached the sixth month follow-up, the mean weekly seizure number before ZNS had been 3.2 ± 5.0, and at final follow-up, the mean weekly seizure number was 0.18 ± 0.41 (P = 0.05).Compared with baseline, we observed stability in all cognitive domains, except for verbal fluency that significantly worsened.Results on QoL tests showed that QoL remained unchanged over time, which could indicate that ZNS did not influence the patients' perceived QoL. CONCLUSIONS: Zonisamide as add-on in our patients seems to be well tolerated and efficacious in controlling seizures. Despite having limitations represented by the fact that our study is observational, with a small study population and a short follow-up period, our results confirm that when choosing an AED, in addition to efficacy, the drug's effect on patients' QoL also needs to be considered, especially for patients facing many psychosocial challenges, such as those with brain tumor-related epilepsy.
[Mh] Termos MeSH primário: Anticonvulsivantes/uso terapêutico
Neoplasias Encefálicas/fisiopatologia
Disfunção Cognitiva/prevenção & controle
Epilepsia/tratamento farmacológico
Isoxazóis/uso terapêutico
Nootrópicos/uso terapêutico
Qualidade de Vida
[Mh] Termos MeSH secundário: Antineoplásicos/efeitos adversos
Antineoplásicos/uso terapêutico
Neoplasias Encefálicas/tratamento farmacológico
Neoplasias Encefálicas/radioterapia
Disfunção Cognitiva/induzido quimicamente
Disfunção Cognitiva/etiologia
Disfunção Cognitiva/fisiopatologia
Terapia Combinada/efeitos adversos
Resistência a Medicamentos
Quimioterapia Combinada/efeitos adversos
Epilepsia/induzido quimicamente
Epilepsia/etiologia
Epilepsia/fisiopatologia
Feminino
Seguimentos
Seres Humanos
Itália
Transtornos da Linguagem/induzido quimicamente
Transtornos da Linguagem/etiologia
Transtornos da Linguagem/fisiopatologia
Transtornos da Linguagem/prevenção & controle
Masculino
Meia-Idade
Projetos Piloto
Radioterapia/efeitos adversos
Índice de Gravidade de Doença
Comportamento Verbal/efeitos dos fármacos
[Pt] Tipo de publicação:JOURNAL ARTICLE; OBSERVATIONAL STUDY
[Nm] Nome de substância:
0 (Anticonvulsants); 0 (Antineoplastic Agents); 0 (Isoxazoles); 0 (Nootropic Agents); 459384H98V (zonisamide)
[Em] Mês de entrada:1803
[Cu] Atualização por classe:180306
[Lr] Data última revisão:
180306
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170429
[St] Status:MEDLINE
[do] DOI:10.1097/WNF.0000000000000218


  2 / 4249 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28464819
[Au] Autor:Imran M; Arshad MS; Butt MS; Kwon JH; Arshad MU; Sultan MT
[Ad] Endereço:Department of Diet and Nutritional Sciences, Imperial College of Business Studies, Lahore, Pakistan.
[Ti] Título:Mangiferin: a natural miracle bioactive compound against lifestyle related disorders.
[So] Source:Lipids Health Dis;16(1):84, 2017 May 02.
[Is] ISSN:1476-511X
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:The current review article is an attempt to explain the therapeutic potential of mangiferin, a bioactive compound of the mango, against lifestyle-related disorders. Mangiferin (2-ß-D-glucopyranosyl-1,3,6,7-tetrahydroxy-9H-xanthen-9-one) can be isolated from higher plants as well as the mango fruit and their byproducts (i.e. peel, seed, and kernel). It possesses several health endorsing properties such as antioxidant, antimicrobial, antidiabetic, antiallergic, anticancer, hypocholesterolemic, and immunomodulatory. It suppresses the activation of peroxisome proliferator activated receptor isoforms by changing the transcription process. Mangiferin protects against different human cancers, including lung, colon, breast, and neuronal cancers, through the suppression of tumor necrosis factor α expression, inducible nitric oxide synthase potential, and proliferation and induction of apoptosis. It also protects against neural and breast cancers by suppressing the expression of matrix metalloproteinase (MMP)-9 and MMP-7 and inhibiting enzymatic activity, metastatic potential, and activation of the ß-catenin pathway. It has the capacity to block lipid peroxidation, in order to provide a shielding effect against physiological threats. Additionally, mangiferin enhances the capacity of the monocyte-macrophage system and possesses antibacterial activity against gram-positive and gram-negative bacteria. This review summarizes the literature pertaining to mangiferin and its associated health claims.
[Mh] Termos MeSH primário: Anti-Inflamatórios/uso terapêutico
Antineoplásicos Fitogênicos/uso terapêutico
Antioxidantes/uso terapêutico
Hipoglicemiantes/uso terapêutico
Nootrópicos/uso terapêutico
Xantonas/uso terapêutico
[Mh] Termos MeSH secundário: Anti-Inflamatórios/química
Anti-Inflamatórios/isolamento & purificação
Antineoplásicos Fitogênicos/química
Antineoplásicos Fitogênicos/isolamento & purificação
Antioxidantes/química
Antioxidantes/isolamento & purificação
Doenças Cardiovasculares/tratamento farmacológico
Doenças Cardiovasculares/patologia
Disfunção Cognitiva/tratamento farmacológico
Disfunção Cognitiva/patologia
Diabetes Mellitus Tipo 2/tratamento farmacológico
Diabetes Mellitus Tipo 2/patologia
Seres Humanos
Hiperlipidemias/tratamento farmacológico
Hiperlipidemias/patologia
Hipoglicemiantes/química
Hipoglicemiantes/isolamento & purificação
Mangifera/química
Neoplasias/tratamento farmacológico
Neoplasias/patologia
Neuralgia/tratamento farmacológico
Neuralgia/patologia
Nootrópicos/química
Nootrópicos/isolamento & purificação
Estresse Oxidativo/efeitos dos fármacos
Xantonas/química
Xantonas/isolamento & purificação
[Pt] Tipo de publicação:JOURNAL ARTICLE; REVIEW
[Nm] Nome de substância:
0 (Anti-Inflammatory Agents); 0 (Antineoplastic Agents, Phytogenic); 0 (Antioxidants); 0 (Hypoglycemic Agents); 0 (Nootropic Agents); 0 (Xanthones); 1M84LD0UMD (mangiferin)
[Em] Mês de entrada:1802
[Cu] Atualização por classe:180219
[Lr] Data última revisão:
180219
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170504
[St] Status:MEDLINE
[do] DOI:10.1186/s12944-017-0449-y


  3 / 4249 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29390538
[Au] Autor:Li M; Lyu JH; Zhang Y; Gao ML; Li WJ; Ma X
[Ad] Endereço:Center for Cognitive Disorders.
[Ti] Título:The clinical efficacy of reminiscence therapy in patients with mild-to-moderate Alzheimer disease: Study protocol for a randomized parallel-design controlled trial.
[So] Source:Medicine (Baltimore);96(51):e9381, 2017 Dec.
[Is] ISSN:1536-5964
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:INTRODUCTION: Alzheimer disease (AD) is one of the most common diseases among the older adults. Currently, various nonpharmacological interventions are used for the treatment of AD. Such as reminiscence therapy is being widely used in Western countries. However, it is often used as an empirical application in China; the evidence-based efficacy of reminiscence therapy in AD patients remains to be determined. Therefore, the aim of this research is to assess the effectives of reminiscence therapy for Chinese elderly. METHODS AND ANALYSIS: This is a randomized parallel-design controlled trial. Mild and moderate AD patients who are in the Beijing Geriatric Hospital, China will be randomized into control and intervention groups (n = 45 for each group). For the intervention group, along with conventional drug therapy, participants will be exposed to a reminiscence therapy of 35 to 45 minutes, 2 times/wk for 12 consecutive weeks. Patients in the control group will undergo conventional drug therapy only. The primary outcome measure will be the differences in Alzheimer disease Assessment Scale-Cognitive Section Score. The secondary outcome measures will be the differences in the Cornell scale for depression in dementia, Neuropsychiatric Inventory score, and Barthel Index scores at baseline, at 4 and 12 weeks of treatment, and 12 weeks after treatment. ETHICS AND DISSEMINATION: The protocols have been approved by the ethics committee of Beijing Geriatric Hospital of China (approval no. 2015-010). Findings will be disseminated through presentation at scientific conferences and in academic journals. TRIAL REGISTRATION: Chinese Clinical Trial Registry identifier ChiCTR-INR-16009505.
[Mh] Termos MeSH primário: Doença de Alzheimer/terapia
Psicoterapia/métodos
[Mh] Termos MeSH secundário: Idoso
Idoso de 80 Anos ou mais
Doença de Alzheimer/diagnóstico
Doença de Alzheimer/psicologia
Protocolos Clínicos
Terapia Combinada
Método Duplo-Cego
Feminino
Seres Humanos
Masculino
Testes Neuropsicológicos
Nootrópicos/uso terapêutico
Escalas de Graduação Psiquiátrica
Índice de Gravidade de Doença
Resultado do Tratamento
[Pt] Tipo de publicação:JOURNAL ARTICLE; RANDOMIZED CONTROLLED TRIAL
[Nm] Nome de substância:
0 (Nootropic Agents)
[Em] Mês de entrada:1802
[Cu] Atualização por classe:180214
[Lr] Data última revisão:
180214
[Sb] Subgrupo de revista:AIM; IM
[Da] Data de entrada para processamento:180203
[St] Status:MEDLINE
[do] DOI:10.1097/MD.0000000000009381


  4 / 4249 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:27771572
[Au] Autor:Rapee RM; Jones MP; Hudson JL; Malhi GS; Lyneham HJ; Schneider SC
[Ad] Endereço:Centre for Emotional Health, Department of Psychology, Macquarie University, Sydney, New South Wales, 2109, Australia. Electronic address: Ron.Rapee@mq.edu.au.
[Ti] Título:d-Cycloserine does not enhance the effects of in vivo exposure among young people with broad-based anxiety disorders.
[So] Source:Behav Res Ther;87:225-231, 2016 12.
[Is] ISSN:1873-622X
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:Use of the partial NMDA receptor agonist d-Cycloserine (DCS) to increase extinction to feared cues among anxious adults has shown mixed, although overall positive effects. Few studies have extended this effect to youth and none have addressed young people with broad-based anxiety such as separation anxiety, social anxiety, or generalised anxiety. In the current trial 51 children and adolescents with diagnosed anxiety disorders, aged 7-14 years received four sessions of graduated, experimenter-led, in vivo exposure to a hierarchy of feared cues relevant to their primary fear. They were randomly allocated to receive either 50 mg of DCS or a matched placebo capsule in a fully double-blind design. Both groups showed large reductions across sessions in their primary fear according to both parent and child report, but there were no significant differences between conditions at any session. The results are consistent with most studies to date of DCS-augmented exposure in young people.
[Mh] Termos MeSH primário: Transtornos de Ansiedade/tratamento farmacológico
Transtornos de Ansiedade/terapia
Ciclosserina/uso terapêutico
Terapia Implosiva
[Mh] Termos MeSH secundário: Adolescente
Criança
Terapia Combinada
Método Duplo-Cego
Feminino
Seres Humanos
Masculino
Nootrópicos/uso terapêutico
[Pt] Tipo de publicação:JOURNAL ARTICLE; RANDOMIZED CONTROLLED TRIAL; RESEARCH SUPPORT, NON-U.S. GOV'T
[Nm] Nome de substância:
0 (Nootropic Agents); 95IK5KI84Z (Cycloserine)
[Em] Mês de entrada:1709
[Cu] Atualização por classe:180203
[Lr] Data última revisão:
180203
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:161025
[St] Status:MEDLINE


  5 / 4249 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28458424
[Au] Autor:Pattanashetti LA; Taranalli AD; Parvatrao V; Malabade RH; Kumar D
[Ad] Endereço:Department of Pharmacology, K.L.E. University's, College of Pharmacy, Belgaum, Karnataka, India.
[Ti] Título:Evaluation of neuroprotective effect of quercetin with donepezil in scopolamine-induced amnesia in rats.
[So] Source:Indian J Pharmacol;49(1):60-64, 2017 Jan-Feb.
[Is] ISSN:1998-3751
[Cp] País de publicação:India
[La] Idioma:eng
[Ab] Resumo:OBJECTIVE: The objective of this study was to evaluate the neuroprotective effect of quercetin with donepezil in scopolamine-induced amnesia in rats. MATERIALS AND METHODS: Five groups of adult male Wistar rats (12 months old) weighing 180-200 g ( = 6) were used. The normal control group received normal saline and test group animals were pretreated orally with quercetin (25 mg/kg), donepezil (3 mg/kg), and a combination of quercetin (25 mg/kg) with donepezil (3 mg/kg), respectively, dosed at every 24 h interval for 14 consecutive days, afterward amnesia was induced by scopolamine (3 mg/kg) on the 14 day through intraperitoneal route. Cognitive performance was assessed by the Morris water maze, elevated plus maze, and passive avoidance paradigm. Acetylcholinesterase enzyme (AchE) level, biochemical markers such as lipid peroxidase (LPO), glutathione (GSH), ß amyloid level, and histopathological study of rat brain were estimated. Statistical analysis was done by one-way analysis of variance, followed by Dunnett's test. ≥ 0.05 was considered statistically significant. RESULTS: Pretreatment with quercetin, donepezil, and their combination showed a significant increase in escape latency, step-through latency, and decreased transfer latency in respective cognitive models of the Morris water maze, passive avoidance test, and elevated plus maze. Further coadministration significantly decreased AchE level, ß amyloid level as compared to individual therapy. Biochemical markers such as elevated GSH, decreased LPO were observed, and histopathological studies revealed the reversal of neuronal damage in the treatment group ( < 0.05) as compared to scopolamine-treated control group. CONCLUSION: Pretreatment with quercetin potentiates the action of donepezil in scopolamine-induced amnesia in rats. The improved cognitive memory could be due to the synergistic effect of the drugs by decreasing AchE level, ß amyloid level, and antioxidant action in rat brain.
[Mh] Termos MeSH primário: Amnésia/prevenção & controle
Indanos/farmacologia
Fármacos Neuroprotetores/farmacologia
Piperidinas/farmacologia
Quercetina/farmacologia
[Mh] Termos MeSH secundário: Animais
Antioxidantes/administração & dosagem
Antioxidantes/farmacologia
Aprendizagem da Esquiva/efeitos dos fármacos
Cognição/efeitos dos fármacos
Modelos Animais de Doenças
Sinergismo Farmacológico
Indanos/administração & dosagem
Masculino
Aprendizagem em Labirinto/efeitos dos fármacos
Memória/efeitos dos fármacos
Fármacos Neuroprotetores/administração & dosagem
Nootrópicos/administração & dosagem
Nootrópicos/farmacologia
Piperidinas/administração & dosagem
Quercetina/administração & dosagem
Ratos
Ratos Wistar
Hidrobrometo de Escopolamina/toxicidade
[Pt] Tipo de publicação:COMPARATIVE STUDY; JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Antioxidants); 0 (Indans); 0 (Neuroprotective Agents); 0 (Nootropic Agents); 0 (Piperidines); 451IFR0GXB (Scopolamine Hydrobromide); 8SSC91326P (donepezil); 9IKM0I5T1E (Quercetin)
[Em] Mês de entrada:1712
[Cu] Atualização por classe:171229
[Lr] Data última revisão:
171229
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170502
[St] Status:MEDLINE
[do] DOI:10.4103/0253-7613.201016


  6 / 4249 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28458415
[Au] Autor:Agarwal S; Patel BM
[Ad] Endereço:Department of Pharmacology, Nirma University, Ahmedabad, Gujarat, India.
[Ti] Título:Is aura around citicoline fading? A systemic review.
[So] Source:Indian J Pharmacol;49(1):4-9, 2017 Jan-Feb.
[Is] ISSN:1998-3751
[Cp] País de publicação:India
[La] Idioma:eng
[Ab] Resumo:Stroke and traumatic brain injury (TBI) are the critical public health and socioeconomic problems throughout the world. At present, citicoline is used as a coadjuvant for the management of acute ischemic stroke (AIS) and TBI in various countries. This systemic review analyzes the beneficial role of citicoline in AIS and TBI. This systemic review is based on "PubMed" and "Science Direct" search results for citicoline role in stroke and TBI. In this systemic review, we included 12 human trials. A meta-analysis was performed on the basis of neurological evaluation, functional evaluation and Glasgow outcome scale, domestic adaptation evaluation outcomes, and cognitive outcome individually. In neurological evaluation, domestic adaptation evaluation, and cognitive outcomes, there was no significant difference in both the citicoline and placebo groups (odds ratio [OR] = 1.04 [0.9-1.2, = 0.583]; OR = 1.1 [0.94-1.27, = 0.209]; OR = 0.953 [0.75-1.2, = 0.691]). In evaluation of functional outcomes, there was significant difference in both groups and OR was 1.18 (1.04-1.34, = 0.01). Functional outcomes were significantly improved by citicoline, but the positive role of this drug in neurological recovery, domestic adaptation, and cognitive outcomes is still a topic of discussion for future.
[Mh] Termos MeSH primário: Lesões Encefálicas Traumáticas/tratamento farmacológico
Isquemia Encefálica/tratamento farmacológico
Citidina Difosfato Colina/uso terapêutico
Acidente Vascular Cerebral/tratamento farmacológico
[Mh] Termos MeSH secundário: Lesões Encefálicas Traumáticas/fisiopatologia
Isquemia Encefálica/fisiopatologia
Cognição/efeitos dos fármacos
Seres Humanos
Nootrópicos/uso terapêutico
Acidente Vascular Cerebral/fisiopatologia
Resultado do Tratamento
[Pt] Tipo de publicação:JOURNAL ARTICLE; META-ANALYSIS; REVIEW
[Nm] Nome de substância:
0 (Nootropic Agents); 536BQ2JVC7 (Cytidine Diphosphate Choline)
[Em] Mês de entrada:1712
[Cu] Atualização por classe:171229
[Lr] Data última revisão:
171229
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170502
[St] Status:MEDLINE
[do] DOI:10.4103/0253-7613.201037


  7 / 4249 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28851764
[Au] Autor:Nishiyama K; Suzuki H; Harasawa T; Suzuki N; Kurimoto E; Kawai T; Maruyama M; Komatsu H; Sakuma K; Shimizu Y; Shimojo M
[Ad] Endereço:CNS Drug Discovery Unit, Research (K.N., H.S., T.H., N.S., E.K., T.K., M.M., H.K., Y.S., M.S.) and Regenerative Medicine Unit (K.S.), Takeda Pharmaceutical Company Limited, Fujisawa, Japan.
[Ti] Título:FTBMT, a Novel and Selective GPR52 Agonist, Demonstrates Antipsychotic-Like and Procognitive Effects in Rodents, Revealing a Potential Therapeutic Agent for Schizophrenia.
[So] Source:J Pharmacol Exp Ther;363(2):253-264, 2017 Nov.
[Is] ISSN:1521-0103
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:GPR52 is a Gs-coupled G protein-coupled receptor that is predominantly expressed in the striatum and nucleus accumbens (NAc) and was recently proposed as a potential therapeutic target for schizophrenia. In the current study, we investigated the in vitro and in vivo pharmacologic activities of a novel GPR52 agonist, 4-(3-(3-fluoro-5-(trifluoromethyl)benzyl)-5-methyl-1 -1,2,4-triazol-1-yl)-2-methylbenzamide (FTBMT). FTBMT functioned as a selective GPR52 agonist in vitro and in vivo, as demonstrated by the activation of Camp signaling in striatal neurons. FTBMT inhibited MK-801-induced hyperactivity, an animal model for acute psychosis, without causing catalepsy in mice. The c-fos expression also revealed that FTBMT preferentially induced neuronal activation in the shell of the Nac compared with the striatum, thereby supporting its antipsychotic-like activity with less catalepsy. Furthermore, FTBMT improved recognition memory in a novel object-recognition test and attenuated MK-801-induced working memory deficits in a radial arm maze test in rats. These recognitive effects were supported by the results of FTBMT-induced c-fos expression in the brain regions related to cognition, including the medial prefrontal cortex, entorhinal cortex, and hippocampus. Taken together, these findings suggest that FTBMT shows antipsychotic and recognitive properties without causing catalepsy in rodents. Given its unique pharmacologic profile, which differs from that of current antipsychotics, FTBMT may provide a new therapeutic option for the treatment of positive and cognitive symptoms of schizophrenia.
[Mh] Termos MeSH primário: Antipsicóticos/uso terapêutico
Benzamidas/uso terapêutico
Modelos Animais de Doenças
Nootrópicos/uso terapêutico
Receptores Acoplados a Proteínas-G/agonistas
Esquizofrenia
Triazóis/uso terapêutico
[Mh] Termos MeSH secundário: Animais
Antipsicóticos/química
Antipsicóticos/farmacologia
Benzamidas/química
Benzamidas/farmacologia
Células CHO
Cricetinae
Cricetulus
Relação Dose-Resposta a Droga
Feminino
Locomoção/efeitos dos fármacos
Locomoção/fisiologia
Masculino
Camundongos
Camundongos Endogâmicos C57BL
Camundongos Endogâmicos ICR
Camundongos Knockout
Nootrópicos/química
Nootrópicos/farmacologia
Núcleo Accumbens/efeitos dos fármacos
Núcleo Accumbens/fisiologia
Técnicas de Cultura de Órgãos
Ratos
Ratos Long-Evans
Ratos Sprague-Dawley
Ratos Wistar
Receptores Acoplados a Proteínas-G/fisiologia
Esquizofrenia/tratamento farmacológico
Resultado do Tratamento
Triazóis/química
Triazóis/farmacologia
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (4-(3-(3-fluoro-5-(trifluoromethyl)benzyl)-5-methyl-1H-1,2,4-triazol-1-yl)-2-methylbenzamide); 0 (Antipsychotic Agents); 0 (Benzamides); 0 (Gpr52 protein, mouse); 0 (Nootropic Agents); 0 (Receptors, G-Protein-Coupled); 0 (Triazoles)
[Em] Mês de entrada:1710
[Cu] Atualização por classe:171030
[Lr] Data última revisão:
171030
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170831
[St] Status:MEDLINE
[do] DOI:10.1124/jpet.117.242925


  8 / 4249 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28827830
[Au] Autor:Chen R; Chan PT; Chu H; Lin YC; Chang PC; Chen CY; Chou KR
[Ad] Endereço:School of Nursing, College of Nursing, Taipei Medical University, Taipei, Taiwan.
[Ti] Título:Treatment effects between monotherapy of donepezil versus combination with memantine for Alzheimer disease: A meta-analysis.
[So] Source:PLoS One;12(8):e0183586, 2017.
[Is] ISSN:1932-6203
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:BACKGROUND: This is the first meta-analysis to compare the treatment effects and safety of administering donepezil alone versus a combination of memantine and donepezil to treat patients with moderate to severe Alzheimer Disease, particularly regarding cognitive functions, behavioral and psychological symptoms in dementia (BPSD), and global functions. METHODS: PubMed, Medline, Embase, PsycINFO, and Cochrane databases were used to search for English and non-English articles for inclusion in the meta-analysis to evaluate the effect size and incidence of adverse drug reactions of different treatments. RESULTS: Compared with patients who received donepezil alone, those who received donepezil in combination with memantine exhibited limited improvements in cognitive functions (g = 0.378, p < .001), BPSD (g = -0.878, p < .001) and global functions (g = -0.585, p = .004). Gradual titration of memantine plus a fixed dose and gradual titration of donepezil as well as a fixed dose and gradual titration of memantine resulted in limited improvements in cognitive functions(g = 0.371, p = .005), BPSD(g = -0.913, p = .001), and global functions(g = -0.371, p = .001). CONCLUSION: Both in the 24th week and at the final evaluation point, the combination of donepezil and memantine led to greater improvement in cognitive functions, BPSD, and global functions than did donepezil alone in patients with moderate to severe Alzheimer Disease.
[Mh] Termos MeSH primário: Doença de Alzheimer/tratamento farmacológico
Indanos/uso terapêutico
Memantina/uso terapêutico
Nootrópicos/uso terapêutico
Piperidinas/uso terapêutico
[Mh] Termos MeSH secundário: Quimioterapia Combinada
Seres Humanos
Indanos/administração & dosagem
Memantina/administração & dosagem
Nootrópicos/administração & dosagem
Piperidinas/administração & dosagem
[Pt] Tipo de publicação:JOURNAL ARTICLE; META-ANALYSIS
[Nm] Nome de substância:
0 (Indans); 0 (Nootropic Agents); 0 (Piperidines); 8SSC91326P (donepezil); W8O17SJF3T (Memantine)
[Em] Mês de entrada:1710
[Cu] Atualização por classe:171013
[Lr] Data última revisão:
171013
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170823
[St] Status:MEDLINE
[do] DOI:10.1371/journal.pone.0183586


  9 / 4249 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28813563
[Au] Autor:Lyon J
[Ti] Título:Chess Study Revives Debate Over Cognition-Enhancing Drugs.
[So] Source:JAMA;318(9):784-786, 2017 Sep 05.
[Is] ISSN:1538-3598
[Cp] País de publicação:United States
[La] Idioma:eng
[Mh] Termos MeSH primário: Estimulantes do Sistema Nervoso Central/farmacologia
Cognição/efeitos dos fármacos
Nootrópicos/farmacologia
Uso Off-Label
[Mh] Termos MeSH secundário: Compostos Benzidrílicos/farmacologia
Compostos Benzidrílicos/uso terapêutico
Jogos Recreativos
Seres Humanos
Masculino
Nootrópicos/uso terapêutico
[Pt] Tipo de publicação:NEWS
[Nm] Nome de substância:
0 (Benzhydryl Compounds); 0 (Central Nervous System Stimulants); 0 (Nootropic Agents); R3UK8X3U3D (modafinil)
[Em] Mês de entrada:1709
[Cu] Atualização por classe:170927
[Lr] Data última revisão:
170927
[Sb] Subgrupo de revista:AIM; IM
[Da] Data de entrada para processamento:170817
[St] Status:MEDLINE
[do] DOI:10.1001/jama.2017.8114


  10 / 4249 MEDLINE  
              first record previous record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28759224
[Au] Autor:Nedelcovych MT; Tenora L; Kim BH; Kelschenbach J; Chao W; Hadas E; Jancarík A; Prchalová E; Zimmermann SC; Dash RP; Gadiano AJ; Garrett C; Furtmüller G; Oh B; Brandacher G; Alt J; Majer P; Volsky DJ; Rais R; Slusher BS
[Ti] Título:N-(Pivaloyloxy)alkoxy-carbonyl Prodrugs of the Glutamine Antagonist 6-Diazo-5-oxo-l-norleucine (DON) as a Potential Treatment for HIV Associated Neurocognitive Disorders.
[So] Source:J Med Chem;60(16):7186-7198, 2017 Aug 24.
[Is] ISSN:1520-4804
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:Aberrant excitatory neurotransmission associated with overproduction of glutamate has been implicated in the development of HIV-associated neurocognitive disorders (HAND). The glutamine antagonist 6-diazo-5-oxo-l-norleucine (DON, 14) attenuates glutamate synthesis in HIV-infected microglia/macrophages, offering therapeutic potential for HAND. We show that 14 prevents manifestation of spatial memory deficits in chimeric EcoHIV-infected mice, a model of HAND. 14 is not clinically available, however, because its development was hampered by peripheral toxicities. We describe the synthesis of several substituted N-(pivaloyloxy)alkoxy-carbonyl prodrugs of 14 designed to circulate inert in plasma and be taken up and biotransformed to 14 in the brain. The lead prodrug, isopropyl 6-diazo-5-oxo-2-(((phenyl(pivaloyloxy)methoxy)carbonyl)amino)hexanoate (13d), was stable in swine and human plasma but liberated 14 in swine brain homogenate. When dosed systemically in swine, 13d provided a 15-fold enhanced CSF-to-plasma ratio and a 9-fold enhanced brain-to-plasma ratio relative to 14, opening a possible clinical path for the treatment of HAND.
[Mh] Termos MeSH primário: Aminocaproatos/farmacologia
Compostos Azo/farmacologia
Diazo-Oxo-Norleucina/farmacologia
Transtornos Neurocognitivos/tratamento farmacológico
Nootrópicos/farmacologia
Pró-Fármacos/farmacologia
[Mh] Termos MeSH secundário: Aminocaproatos/administração & dosagem
Aminocaproatos/síntese química
Animais
Compostos Azo/administração & dosagem
Compostos Azo/síntese química
Sangue/metabolismo
Encéfalo/metabolismo
Diazo-Oxo-Norleucina/administração & dosagem
Estabilidade de Medicamentos
Feminino
Ácido Glutâmico/metabolismo
Glutaminase/antagonistas & inibidores
Infecções por HIV/complicações
Seres Humanos
Masculino
Camundongos Endogâmicos C57BL
Transtornos Neurocognitivos/etiologia
Nootrópicos/administração & dosagem
Nootrópicos/síntese química
Pró-Fármacos/administração & dosagem
Pró-Fármacos/síntese química
Suínos
Carga Viral/efeitos dos fármacos
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Aminocaproates); 0 (Azo Compounds); 0 (Nootropic Agents); 0 (Prodrugs); 0 (isopropyl 6-diazo-5-oxo-2-(((phenyl(pivaloyloxy)methoxy)carbonyl)amino)hexanoate); 03J0H273KZ (Diazooxonorleucine); 3KX376GY7L (Glutamic Acid); EC 3.5.1.2 (Glutaminase)
[Em] Mês de entrada:1709
[Cu] Atualização por classe:170926
[Lr] Data última revisão:
170926
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170801
[St] Status:MEDLINE
[do] DOI:10.1021/acs.jmedchem.7b00966



página 1 de 425 ir para página                         
   


Refinar a pesquisa
  Base de dados : MEDLINE Formulário avançado   

    Pesquisar no campo  
1  
2
3
 
           



Search engine: iAH v2.6 powered by WWWISIS

BIREME/OPAS/OMS - Centro Latino-Americano e do Caribe de Informação em Ciências da Saúde